

1636 Box Sea

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Robert P. Hebbel et al.

Title:

TRANSGENIC CIRCULATING ENDOTHELIAL CELLS

Docket No.:

600.449US1

Filed:

May 24, 2001

Examiner:

Serial No.: 09/865,022 Due Date: October 2, 2001

Group Art Unit: 1636

Commissioner for Patents

Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

 $\underline{X}$  A return postcard.

X Preliminary Amendment (1 Page).

An Information Disclosure Statement (1 pgs.), Form 1449 (1 pgs.), and copies of 14 cited references.

Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure (2 pgs.).

 $\underline{X}$  Sequence Listing (7 pgs.).

X Sequence Listing in ASCII computer readable form.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

Atty: Janet E. Embretson

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 200 day of October, 2001.

Name


Signature

**Customer Number 21186** 

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)



COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE Washington, D.C. 20231

www.uspto.gov APPLICATION NUMBER FILING/RECEIPT DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER 09/865,022 05/24/2001 Robert P. Hebbel

600.449US1

21186 SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH P.O. BOX 2938 MINNEAPOLIS, MN 55402

**CONFIRMATION NO. 3307** FORMALITIES LETTER \*OC000000006375458\*

Date Mailed: 08/02/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES** 

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice MUST be returned with the reply.

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE

tional Application No PCT/US 99/28033

CLASSIFICATION OF SUBJECT MATTER PC 7 C12N5/06 C12N5/08

C12Q1/02

A61P7/04

C12N5/10 //C07K14/755 A61K48/00

A61L27/38

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symposs) IPC 7 C12N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	ENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
		110-00-11110-010111110.
X	WO 96 15777 A (US HEALTH) 30 May 1996 (1996-05-30) example 5	15-26,32
X	US 5 674 722 A (BIRINYI LOUIS K ET AL) 7 October 1997 (1997-10-07) column 2, line 51 -column 3, line 47 column 13, line 43 -column 15, line 33 claims 1,22,34,39,45; example 7	15-29, 31,32
X	WO 90 06997 A (US GOVERNMENT ;UNIV MIAMI (US)) 28 June 1990 (1990-06-28) page 8, paragraph 2 -page 9, line 18; claims 1-33 page 4, paragraph 4 -page 5, paragraph 3	15-26, 30,32
	-/	

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.				
* Special categories of cited documents :					
"A" document defining the general state of the art which is not considered to be of particular relevance	T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention				
"E" earlier document but published on or after the international filing date	"X" document of particular relevance; the claimed invention				
"L" document which may throw doubts on phority claims) or	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone				
which is cred to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention				
"O" document referring to an oral disclosure, use, exhibition or other means.	cannot be considered to involve an inventive step when the document is combined with one or more other such docu-				
"P" document published prior to the international filing date but	ments, such combination being obvious to a person skilled in the art.				
later than the priority date claimed	"&" document member of the same patent family				
Date of the actual completion of the international search	Date of mailing of the international search report				
13 April 2000	08/05/2000				
Name and mailing address of the ISA	Authorized officer				
European Patent Office, P.B. 5618 Patentiaan 2 NL = 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Fernandez y Branas,F				

Int. Jonal Application No PCT/US 99/28033

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
ategory ·	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to dam No.	
x	SOLOVEY ANNA ET AL: "Tissue factor expression by endothelial cells in sickle cell anemia."  JOURNAL OF CLINICAL INVESTIGATION MAY 1, 1998,  vol. 101, no. 9, 1 May 1998 (1998-05-01), pages 1899-1904, XP000891886  ISSN: 0021-9738  abstract page 1903	33-36	
x	WO 98 19712 A (ST ELIZABETH S MEDICAL CENTER) 14 May 1998 (1998-05-14) page 25 -page 31; claims 1-23	17,22,23	
A	WO 95 24427 A (UNIV EMORY ;LOLLAR JOHN S (US); RUNGE MARSCHALL S (US)) 14 September 1995 (1995-09-14) the whole document	15-26	
۹.	US 5 563 045 A (PITTMAN DEBRA ET AL) 8 October 1996 (1996-10-08) the whole document	15-26	
A	SENGER DONALD R ET AL: "Angiogenesis promoted by vascular endothelial growth factor: Regulation through alphalbetal and alpha2betal integrins." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA DEC. 9, 1997, vol. 94, no. 25, 9 December 1997 (1997-12-09), pages 13612-13617, XP002135444 ISSN: 0027-8424 abstract page 13614, column 2, paragraph 1	1-14	
	SHI QUN ET AL: "Evidence for circulating bone marrow-derived endothelial cells" BL00D, vol. 92, no. 2, July 1998 (1998-07), pages 362-367, XP002135445 cited in the application the whole document ————————————————————————————————————	1-14	

Inte. onal Application No PCT/US 99/28033

C.(Continua	Rtion) DOCUMENTS CONSIDERED TO BE RELEVANT	PCT/US 99/28033
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
		The state of the s
4	LIN Y ET AL: "Circulating endothelial cells are from vessel wall, but peripheral blood endothelial outgrowth is from a marrow-derived cell."  40TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; MIAMI BEACH, FLORIDA, USA; DECEMBER 4-8, 1998, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), page 152A XP000891920 Blood Nov. 15, 1998 ISSN: 0006-4971 abstract	1-14
	GNATENKO D ET AL: "An adeno-associated/adenovirus hybrid vector generates high-level human factor VIII in vitro."  40TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY; MIAMI BEACH, FLORIDA, USA; DECEMBER 4-8, 1998, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), page 146A XP000891953 Blood Nov. 15, 1998 ISSN: 0006-4971 the whole document	15-26
	US 5 132 223 A (LEVINE ELLIOT M ET AL) 21 July 1992 (1992-07-21) the whole document	1-14

...emational application No.

PCT/US 99/28033

Box I Observat	and whose section of the
	ons where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Se	arch Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos because the Remark:	:  Py relate to subject matter not required to be searched by this Authority, namely:  Although claims 25-26 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos. because the an extent th	: y relate to parts of the International Application that do not compty with the prescribed requirements to such at no meaningful International Search can be carried out, specifically:
	y are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observation	ons where unity of invention is lacking (Continuation of Item 2 of first sheet)
This International Sea	rching Authority found multiple inventions in this international application, as follows:
As all require searchable cl	d additional search fees were timely paid by the applicant, this International Search Report covers all aims.
2. As all searche of any addition	uble claims could be searched without effort justifying an additional fee, this Authority did not invite payment nal fee.
As only some covers only the	of the required additional search fees were timely paid by the applicant, this International Search Report ose claims for which fees were paid, specifically claims Nos.:
No required acrestricted to the	difficial search fees were timely paid by the applicant. Consequently, this International Search Report is a invention first mentioned in the claims; it is covered by claims Nos.;
Remark on Protest	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.

Information on patent family members

Inter anal Application No PCT/US 99/28033

Patent document cited in search repo	ert .	Publication date	I	Patent family member(s)		Publication date
WO 9615777	A	30-05-1996	CA	2205874	A	30-05-1996
			EP	0786989	Α	06-08-1997
			JP	10509046	T 	08-09-1998
U\$ 5674722	Α	07-10-1997	UŞ	6001350		14-12-1999
			AT		Ţ	15-02-1998
			AT	147102		15-01-1997
			AU	659824		01-06-1995
			AU	1266692		26-05-1992
			AU AU	656544 9017591		09-02-1995
			CA	2095153		26-05-1992 01-05-1992
			CA	2095256		01-05-1992
			DE	69123981		13-02-1997
			DE		T	05-06-1997
			DE	69128893		12-03-1998
			DE		Ť	10-09-1998
			DK	556345	T	16-06-1997
			EP	0568537		10-11-1993
			EP	0556345		25-08-1993
			ES		Ţ	01-07-1998
			ES		T	16-03-1997
			GR		Ţ	30-06-1997
			JP		Ť	06-04-1995
			JP WO	6503968 9207943	T A	12-05-1994 14-05-1992
			WO		A A	14-05-1992
			AT		T T	15-09-1994
		•	CA	1340427		09-03-1999
			DE		Ď	22-09-1994
			DΕ		Ť	05-01-1995
			EP	0391960	A	17-10-1990
			HK		A	07-05-1999
			JP	2914692		05-07-1999
			JP		Ţ	07-11-1991
			WO	8905345	A 	15-06-1989
WO 9006997	Α	28-06-1990	CA	2005199		13-06-1990
			EP Jp	0456640 4507041		21-11-1991 10-12-1992
			UF			
WN 9819712	A	14-05-1998	US	5980887		09-11-1999
			AU	5243298		29-05-1998
			EP	0941125	A 	15-09-1999
WO 9524427	Α	14-09-1995	US	5663060		02-09-1997
			AU	693837		09-07-1998
			AU	1209695		25-09-1995
			CA	2185327		14-09-1995 27 <b>-</b> 12-1996
			EP Jp	0749444 10500282		13-01-1998
			US	5744446		28-04-1998
			US	5888974		30-03-1999
			US	5859204		12-01-1999
US 5563045	Α	08-10-1996	AU	5298293	 A	08-06-1994
00 000040	••	00 10 1770	ΕP	0672138		20-09-1995
						26-05-1994
			WO	9411503	A	יצעודכטדם



Information on patent family members

Inter anal Application No PCT/US 99/28033

Patent document cited in search report		Publication date			Publication date
US 5132223	Α	21-07-1992	CA EP US	1204399 A 0142344 A 4994387 A	13-05-1986 22-05-1985 19-02-1991

Form PCT/ISA/210 (patent family armex) (July 1992)